EGFR and non-small cell lung carcinoma: In several human tumors, including non-small cell lung cancer, high ILK and LIMS1 expression correlates with increased disease progression38,39 and in EGFR-mutant patients, correlates with significantly worse progression-free survival after treatment with EGFR inhibitors40.